Expertise in
1
conditions

Dr. Richard C. Lauer

Hematology
University Of New Mexico Medical Group Inc
933 Bradbury Dr SE Ste 2222, 
Albuquerque, NM 
Expertise in
1
conditions
University Of New Mexico Medical Group Inc
933 Bradbury Dr SE Ste 2222, 
Albuquerque, NM 

Overview

Richard Lauer is a Hematologist practicing medicine in Albuquerque, New Mexico.

Dr. Lauer is highly rated in 1 condition, according to our data. His clinical expertise encompasses Multiple Myeloma, Autoimmune Hemolytic Anemia, Transient Erythroblastopenia of Childhood, and Muscle Invasive Bladder Cancer.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NM

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

University of New Mexico Medical Group Inc
933 Bradbury Dr SE Ste 2222, Albuquerque, NM 87106
Other Locations
Office
Albuquerque, NM 87102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

11 Total Publications

Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Journal: eLife
Published: July 16, 2022
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of New Mexico Ems Consortium

1 University Of New Mexico, 
Albuquerque, NM 
 (2.0 miles away)
505-272-4946
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Andritsos is a Hematologist practicing medicine in Albuquerque, New Mexico. Dr. Andritsos is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Hairy Cell Leukemia (HCL), Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Splenectomy.

Expertise in
47
conditions
Dr. Annette Fontaine
Hematology | Oncology
Expertise in
47
conditions
Dr. Annette Fontaine
Hematology | Oncology
Referral may be required

New Mexico Oncology Hematology Consultants, Ltd

4901 Lang Ave Ne, 
Albuquerque, NM 
 (8.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Annette Fontaine is a Hematologist and an Oncologist practicing medicine in Albuquerque, New Mexico. Dr. Fontaine is highly rated in 47 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, Bone Marrow Aspiration, and Salpingo-Oophorectomy. Dr. Fontaine is board certified in American Board Of Internal Medicine. Dr. Fontaine is currently accepting new patients.

Expertise in
15
conditions
Dr. Matthew L. Fero
Hematology | Oncology
Expertise in
15
conditions
Dr. Matthew L. Fero
Hematology | Oncology
Referral may be required

University Of New Mexico Hospitals

2211 Lomas Blvd NE, 
Albuquerque, NM 
 (2.1 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Fero is a Hematologist and an Oncologist practicing medicine in Albuquerque, New Mexico. Dr. Fero is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Multiple Myeloma, Classical Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL).

Frequently Asked Questions about Dr. Richard C. Lauer

How do I make an appointment with Dr. Richard C. Lauer?

You can book an appointment with Dr. Richard C. Lauer by calling their office at 505-272-4946. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard C. Lauer a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard C. Lauer is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard C. Lauer specialize in?

While Dr. Richard C. Lauer is a Hematology, they have specific expertise in Multiple Myeloma, Autoimmune Hemolytic Anemia, and Transient Erythroblastopenia of Childhood. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Richard C. Lauer participate in research or clinical trials?

Yes. Dr. Richard C. Lauer has published 11 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Richard C. Lauer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lauer's expertise for a condition
ConditionClose
      View All 44 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile